What's new

Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised

Apr 15, 2025 - 16:48
 0
Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised
Human medicines European public assessment report (EPAR): Zefylti, filgrastim, Date of authorisation: 12/02/2025, Revision: 1, Status: Authorised
Read More

Tags:

Previous Article

Illumina teams up with Tempus to expand DNA profiling beyond cancer

Next Article

Tesco F&F’s online relaunch: what we know so far

Related Posts

Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel) Treatment of Wiskott-Aldrich syndrome, 07/10/2013 Withdrawn

Orphan designation: Autologous CD34+ cells transfected ...

Feb 20, 2025  0

Summary of opinion: Calquence, 27/02/2025 Positive

Summary of opinion: Calquence, 27/02/2025 Positive

Feb 28, 2025  0

Human medicines European public assessment report (EPAR): Jaypirca, pirtobrutinib, Date of authorisation: 30/10/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 9, 2025  0